Can bluebird bio Recover From Another Major Setback?

Shares of bluebird bio (NASDAQ:BLUE) recently took a pounding after the company's lead candidate hit a snag that investors find all too familiar. The company will no longer be applying for approval of bb1111 as a treatment for sickle cell disease (SCD) in the second half of 2021 as previously expected. Instead, Bluebird will spend about a year proving it can manufacture commercial-grade bb1111 identical to the product used in clinical trials supporting its application.